anvisa-mcp
Related Servers
Alternatives to anvisa-mcp
No user-submitted related servers found.
Related Servers
- AlicenseAqualityDmaintenanceEnables LLMs to search FDA drug labels and adverse event data via the OpenFDA API, supporting natural language queries for drug safety information.2MIT
- FlicenseNot gradedqualityDmaintenanceEnables AI agents to query and analyze FDA adverse events, drug labels, medical device clearances, and other public health datasets through natural language commands.14-
- AlicenseNot gradedqualityCmaintenanceMCP server for querying the official ANVISA electronic drug bulletin from a trusted source. It provides a single read-only tool for consulting drug information through natural language in any MCP-compatible client.MIT
- AlicenseAqualityDmaintenanceProvides LLM-optimized access to FDA data through the OpenFDA API and direct regulatory decision document retrieval, covering all 21 OpenFDA endpoints plus 510(k) summaries, De Novo decisions, and PMA approvals.41MIT
- FlicenseNot gradedqualityDmaintenanceEnables AI agents to access FDA and ClinicalTrials.gov data for medical device compliance, adverse event monitoring, and regulatory due diligence.-
- AlicenseNot gradedqualityFmaintenanceProvides comprehensive pharmaceutical intelligence by integrating real-time openFDA data with locally-cached Orange Book and Purple Book databases. It enables users to analyze drug safety, patents, generic equivalents, biosimilars, and regulatory information through natural language queries.3MIT
TDQS
Scored across 2 tools
The two tools operate in completely separate domains: one retrieves recent Class III/IV medical devices with AI classification, the other queries drug registration status. There is no overlap or ambiguity between them.
Both tool names follow the same verb_noun pattern in Portuguese: buscar_samd_recentes and consultar_status_medicamento. The naming is clean, descriptive, and consistent.
With only two tools, the server feels thin for the broad regulatory scope of Anvisa. The count is borderline acceptable because each tool covers a distinct product category, but it leaves many common regulatory queries unaddressed.
The device tool only covers recent SaMD registrations with a heuristic AI filter, and the drug tool only checks registration status. There are significant gaps such as searching devices by name/number, retrieving full regulatory details, or covering other Anvisa-regulated product types.